ArticleBioscience reports2026
Hepatic iron accumulation is reduced in the cholestatic Mdr2-/- mouse.
Article in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The multidrug-resistance 2 (Mdr2-/-) mouse is an animal model of biliary liver injury and fibrosis. This genetic equivalent of the human disorder progressive familial intrahepatic cholestasis type 3 histologically resembles primary sclerosing cholangitis. Bile acid accumulation during cholestasis is linked to the down-regulation of the iron regulatory hormone hepcidin, thus suggesting a link between liver disease and iron homeostasis. In the present study, we investigated iron homeostasis in the Mdr2-/- mouse model of cholestasis. Iron levels and expression of iron-related genes were analysed by real-time PCR and western blotting. Accumulation of iron and the hepcidin response were analysed in wild-type and Mdr2-/- mice challenged with either an iron-deficient or a 1% carbonyl iron diet. Mdr2-/- mice on a control diet had reduced hepatic iron stores when compared with age-matched controls, despite lower hepatic hepcidin expression and a corresponding elevation in hepatic transferrin receptor 1 expression. Mdr2-/- mice fed a 1% carbonyl iron diet were resistant to hepatic iron accumulation, despite increased serum iron, suggesting impaired hepatocyte iron uptake in this model. In conclusion, Mdr2-/- have abnormal hepatic iron homeostasis, potentially resulting from cholestasis. Impaired hepatic iron uptake may explain the relative paucity of liver iron in cholestatic compared with hepatocellular conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.